Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma

Molecular Medicine Reports

Volumn 6, Issue 3, 2012, Pages 477-482

  Li, Yuan ^a   Zhang, Yongli ^a   Fu, Mingming ^a   Yao, Qin ^a   Zhuo, Huiqin ^a   Lu, Quanyi ^a   Niu, Xiaoqing ^a   Zhang, Peng ^a   Pei, Yihua ^a   Zhang, Kejie ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Burkitt lymphoma; Epstein Barr virus; Lytic replication; Parthenolide

Indexed keywords

GANCICLOVIR; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN BRLF1; IMMEDIATE EARLY PROTEIN BZLF1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARTHENOLIDE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; HUMAN CELL; LYMPHOMA CELL; WESTERN BLOTTING;

ANTIVIRAL AGENTS; APOPTOSIS; BURKITT LYMPHOMA; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS INFECTIONS; GANCICLOVIR; HERPESVIRUS 4, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; NF-KAPPA B; PLANTS, MEDICINAL; SESQUITERPENES; TANACETUM PARTHENIUM; TRANS-ACTIVATORS;

EID: 84865163278     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.959     Document Type: Article

References (36)

1. Yang L, Parkin DM, Whelan S, Zhang S, Chen Y, Lu F and Li L: Statistics on cancer in China: cancer registration in 2002. Eur J Cancer Prev 14: 329-335, 2005. (Pubitemid 41104940)
2. Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044, 2006.
3. Cohen JI, Kimura H, Nakamura S, Ko YH and Jaffe ES: Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 20: 1472-1482, 2009.
4. Thorley-Lawson DA and Gross A: Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350: 1328-1337, 2004. (Pubitemid 38375368)
5. Thorley-Lawson DA and Allday MJ: The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 6: 913-924, 2008.
6. Cohen JI, Bollard CM, Khanna R and Pittaluga S: Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma 49 Suppl 1: 27-34, 2008.
7. Perrine SP, Hermine O, Small T, et al: A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109: 2571-2578, 2007. (Pubitemid 46425904)
8. Fu DX, Tanhehco Y, Chen J, et al: Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med 14: 1118-1122, 2008.
9. Landais E, Saulquin X, Scotet E, et al: Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 103: 1408-1416, 2004. (Pubitemid 38168656)
10. Feng WH, Israel B, Raab-Traub N, Busson P and Kenney SC: Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 62: 1920-1926, 2002. (Pubitemid 34408523)
11. Hailfinger S, Nogai H, Pelzer C, et al: Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci USA 108: 14596-14601, 2011.
12. Song YJ and Kang MS: Roles of TRAF2 and TRAF3 in Epstein-Barr virus latent membrane protein 1-induced alternative NF-kappaB activation. Virus Genes 41: 174-180, 2010.
13. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J and Kieff E: NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA 97: 6055-6060, 2000. (Pubitemid 30367522)
14. Chaudhary PM, Jasmin A, Eby MT and Hood L: Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 18: 5738-5746, 1999. (Pubitemid 29507427)
15. Izumi KM and Kieff ED: The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 94: 12592-12597, 1997.
16. Keller SA, Schattner EJ and Cesarman E: Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96: 2537-2542, 2000.
17. Smolinski AT and Pestka JJ: Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver. J Inflamm (Lond) 2: 6, 2005.
18. Pareek A, Suthar M, Rathore GS and Bansal V: Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn Rev 5: 103-110, 2011.
19. deGraffenried LA, Chandrasekar B, Friedrichs WE, et al: NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 15: 885-890, 2004. (Pubitemid 39004343)
20. Nakshatri H, Rice SE and Bhat-Nakshatri P: Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23: 7330-7344, 2004. (Pubitemid 39382136)
21. Dai Y, Guzman ML, Chen S, et al: The NF (Nuclear factor)-kappaB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol 151: 70-83, 2010.
22. Israel BF and Kenney SC: Virally targeted therapies for EBV-associated malignancies. Oncogene 22: 5122-5130, 2003. (Pubitemid 37059593)
23. Flemington EK: Herpesvirus lytic replication and the cell cycle: arresting new developments. J Virol 75: 4475-4481, 2001.
24. Wang H, Zhao Y, Zeng L, Tang M, El-Deeb A, Li JJ and Cao Y: BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells. Anticancer Res 24: 67-74, 2004. (Pubitemid 38279689)
25. Chen YL, Law PY and Loh HH: Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents 5: 575-589, 2005. (Pubitemid 41601056)
26. Feng WH and Kenney SC: Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 66: 8762-8769, 2006.
27. Urier G, Buisson M, Chambard P and Sergeant A: The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J 8: 1447-1453, 1989. (Pubitemid 19274370)
28. Zalani S, Holley-Guthrie E and Kenney S: Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci USA 93: 9194-9199, 1996. (Pubitemid 26282040)
29. Mogensen TH and Paludan SR: Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev 65: 131-150, 2001. (Pubitemid 32204291)
30. Hiscott J, Kwon H and Genin P: Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest 107: 143-151, 2001. (Pubitemid 32096827)
31. Santoro MG, Rossi A and Amici C: NF-kappaB and virus infection: who controls whom. EMBO J 22: 2552-2560, 2003. (Pubitemid 36712353)
32. Brown HJ, Song MJ, Deng H, Wu TT, Cheng G and Sun R: NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol 77: 8532-8540, 2003. (Pubitemid 36871481)
33. Kwok BH, Koh B, Ndubuisi MI, Elofsson M and Crews CM: The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 8: 759-766, 2001. (Pubitemid 32752455)
34. Hayashi S, Koshiba K, Hatashita M, et al: Thermosensitization and induction of apoptosis or cell-cycle arrest human prostate cancer androgen-independent cell lines. Int J Mol Med 28: 1033-1042, 2011.
35. Gunn EJ, Williams JT, Huynh DT, et al: The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma. Leuk Lymphoma 52: 1085-1097, 2011.
36. Ghashghaeinia M, Toulany M, Saki M, et al: The NFkB pathway inhibitors Bay 11-7082 and parthenolide induce programmed cell death in anucleated Erythrocytes. Cell Physiol Biochem 27: 45-54, 2011.